Abstract
Purpose. Our main aim is to determine the effective intestinal permeability (Peff) in the rat jejunum in situ for 10 compounds with different absorption mechanisms and a broad range of physico chemical properties, and then compare them with corresponding historical human in vivo Peff values.
Methods. The rat Peff coefficients are determined using an in situ perfusion model in anaesthetized animals. The perfusion flow rate used is 0.2 ml/min, which is 10 times lower than that used in humans. The viability of the method is assessed by testing the physiological function of the rat intestine during perfusions.
Results. The Peff for passively absorbed compounds is on average 3.6 times higher in humans compared to rats (Peff,man = 3.6 · Peff,rat + 0.03·10−4; R^2 = 1.00). Solutes with carrier-mediated absorption deviate from this relationship, which indicates that an absolute scaling of active processes from animal to man is difficult, and therefore needs further investigation. The fraction absorbed of drugs after oral administration in humans (fa) can be estimated from 1 − e−(2·P eff,man ·t res /r·2.8).
Conclusions. Rat and human jejunum Peff estimates of passively absorbed solutes correlate highly, and both can be used with precision to predict in vivo oral absorption in man. The carrier-mediated transport requires scaling between the models, since the transport maximum and/or substrate specificity might differ. Finally, we emphasize the absolute necessity of including marker compounds for continuous monitoring of intestinal viability.
Similar content being viewed by others
REFERENCES
U. Fagerholm and H. Lennernäs. Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral drug absorption. Eur. J. Pharm. Sci., 3:247–53 (1995).
A. Walter and J. Gutknecht. Permeability of small nonelectrolytes through lipid bilayer membranes. J. Membrane Biol., 90:207–17 (1986).
J. S. Trier and J. L. Madara. Chapter 35: Functional morphology of the mucosa of the small intestine. In Physiology of the gastrointestinal tract (2nd edition). Ed. L. R. Johnson. Raven Press, New York, 1981, pp. 925–61.
D. C. Taylor, J. Lynch, and D. E. Leahy. Chapter 11: Models for intestinal permeability to drugs. In Drug delivery to the gastrointestinal tract, Ed. J. G. Hardy, S. S. Davis and C. G. Wilson. Chichester, U. K. Ellis Horwood Ltd., 1989, pp. 133–45.
H. Lennernäs, Ö Ahrenstedt, and A-L. Ungell. Intestinal drug absorption during induced net water absorption in man: A mechanistic study using antipyrine, atenolol and enalaprilat. Br. J. Clin. Pharmacol., 37:589–96 (1994).
D. Nilsson, U. Fagerholm, and H. Lennernäs. The influence of net water absorption on the permeability of antipyrine and levodopa in the human jejunum. Pharm. Res., 11:1541–5 (1994).
U. Fagerholm, L. Borgström, Ö Ahrenstedt, and H. Lennernäs. The lack of effect of induced net fluid absorption on the in vivo permeability of terbutaline in the human jejunum. J. Drug Targeting, 3:191–200 (1995).
H. Lennernäs. Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation? Pharm. Res., 12:1573–82 (1995).
M. R. Uhing and R. E. Kimura. Active transport of 3-O-methyl-glucose by the small intestine in chronically catheterized rats. J. Clin. Invest., 95:2799–805 (1995).
J. M. Diamond. News and views: How to be physiological. Nature, 376:117–8 (1995).
H. Lennernäs, Ö Ahrenstedt, R. Hällgren, L. Knutson, M. Ryde, and L. Paalzow Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm. Res., 9:1243–51 (1992).
H. Lennernäs, D. Nilsson, S-M. Aquilonius, Ö. Ahrenstedt, L. Knutson, and L. Paalzow. The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br. J. Clin. Pharmacol., 35:243–50 (1993).
H. Lennernäs, L. Knutson, T. Knutson, L. Lesko, T. Salomonson, and G. L. Amidon. Human effective permeability data for atenolol, metoprolol and carbamazepine to be used in the proposed biopharmaceutical classification for IR-products. Pharm. Res., 12:295 (1995).
H. Lennernäs, L. Knutson, T. Knutson, L. Lesko, T. Salomonson, and G. L. Amidon. Human effective permeability data for furosemide, hydrochlortiazide, ketoprofen and naproxen to be used in the proposed biopharmaceutical classification for IR-products. Pharm. Res., 12:396 (1995).
G. L. Amidon, P. J. Sinko, and D. Fleisher. Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm. Res., 5:651–4 (1988).
R. Schultz and D. Winne. Relationship between antipyrine absorption and blood flow rate in rat jejunum, ileum and colon. Naunyn-Schm. Arch Pharmacol, 335:97–102 (1987).
I-D. Lee, U. Fagerholm, H. Lennernäs, and G. Amidon. A study of hydrodynamic characteristics in human intestine applying residence time distribution analysis. Urtti Arto Ed. In Symposium on methods to overcome biological barriers in drug delivery. August 26–28, Kuopio University Publications A Pharm. Sci., 10:p73 (1993).
G. L. Amidon, J. Kou, R. L. Elliot, and E. N. Lightfood. Analysis of models for determining intestinal wall permeabilities. J. Pharm. Sci., 69:1369–73 (1980).
M. D. Levitt, J. M. Kneip, and D. G. Levitt. Use of laminar flow and unstirred layer models to predict intestinal absorption in the rat. J. Clin. Invest. 81:1365–9 (1988).
I. Komiya, J. Y. Park, A. Kamani, N. F. H. Ho, and W. I. Higuchi. Quantitative mechanistic studies in simultaneous fluid flow and intestinal absorption using steroids as model solutes. Int. J. Pharmaceutics, 4,249–62 (1980).
P. J. Sinko, G. D. Leesman, and G. L. Amidon. Predicting fraction absorbed in humans using a macroscopic mass balance approach. Pharm. Res., 8:979–88 (1991).
G. L. Amidon, H. Lennernäs, V. Shah, and J. Crison. A theoretical basis for a biopharmaceutical drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 12:413–20 (1995).
R. D. Purves. MINIM 3.0. A Macintosh application for non-linear parameter estimation, 1994.
H. Yuasa, K. Matsuda, and J. Watanabe. Influence of anaesthetic regimens on intestinal absorption in rats. Pharm. Res., 10:884–8 (1993).
D. Winne, H. Görig, and U. Müller. Closed rat jejunal segment in situ: role of pre-epithelial diffusion resistance (unstirred layer) in the absorption process and model analysis. Naunyn-Schm. Arch Pharmacol., 335:204–15 (1987).
J. R. Pappenheimer and K. Z. Reiss. Contribution of solvent drag through intercellular junctions to absorption of nutrients by the small intestine of the rat. J. Membrane Biol., 100:123–36 (1987).
U. Fagerholm and H. Lennernäs. Experimental investigation of the effects of transmucosal fluid flow on the jejunal uptake of D2O and hydrophilic compounds in man and rat. Pharm. Res., 12:296 (1995).
Clarke's Isolation and Identification of Drugs, 2nd edition. Ed. A. C. Moffat. The Pharmaceutical Press, London, 1986.
Therapeutic Drugs. Ed. Sir C. Dollery. Churchill Livingstone, New York, 1991.
R. F. Rekker and R. Mannhold. In Calculation of Drug Lipophilicity. VCH Publishers, Weinheim, New York, Basel, Cambridge, 1992.
T. Itoh, R. Magavi, R. L. Casady, T. Nishihata, and J. H. Rytting. A method to predict percutaneous permeability of various compounds: Shed snake skin as a model membrane. Pharm. Res., 7:1302–6 (1990).
A. Sandberg. Extended-release metoprolol. Dissertation thesis, Uppsala, 1994.
P. Artursson and J. Karlsson. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Comm., 175:880–5 (1991).
Martindale, 27th edition. Ed. A. Wade, The Pharmaceutical Press, London, 1977.
G. Paintaud. Kinetics of drug absorption and influence of absorption rate on pharmacological effect. Dissertation thesis, Stockholm, 1993.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fagerholm, U., Johansson, M. & Lennernäs, H. Comparison Between Permeability Coefficients in Rat and Human Jejunum. Pharm Res 13, 1336–1342 (1996). https://doi.org/10.1023/A:1016065715308
Issue Date:
DOI: https://doi.org/10.1023/A:1016065715308